文献速递糖尿病

每周一次基础胰岛素Fc在未使用胰岛素的2型糖尿病患者中血糖控制与每日一次德谷胰岛素相似:一项2期随机对照试验

Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial.
PubMed 文献 · Diabetes Care · 2023-01-01

该2期随机、平行、开放标签研究纳入278例未使用胰岛素的2型糖尿病患者,1:1随机接受每周一次基础胰岛素Fc(BIF)或每日一次德谷胰岛素治疗26周,两组均滴定至空腹血糖80-100 mg/dL。主要终点HbA1c自基线变化显示BIF非劣效于德谷胰岛素,治疗差异0.06%(90%CI -0.11, 0.24;P=0.56)。两组低血糖发生率低且无显著差异,无严重低血糖。

要点

  • 每周一次BIF在未使用胰岛素的2型糖尿病患者中HbA1c降幅非劣效于每日一次德谷胰岛素。
  • 2级低血糖发生率BIF组0.22事件/患者/年 vs 德谷胰岛素组0.15事件/患者/年,P=0.64,无严重低血糖。
  • 两组治疗中出现的不良事件发生情况相似。

核心结论

  • 每周一次BIF实现了与德谷胰岛素相似的优良血糖控制,未观察到令人担忧的低血糖或其他安全性发现。

研究设计与样本

  • 随机、平行、开放标签的2期研究,纳入278例既往接受口服降糖药治疗、未使用胰岛素的2型糖尿病患者,1:1随机接受每周一次BIF或每日一次德谷胰岛素治疗26周。
  • 两组均滴定至空腹血糖80-100 mg/dL(4.4至<5.6 mmol/L)。
  • 主要终点为HbA1c自基线至第26周的变化(非劣效界值0.4%)。

主要发现

  • 第26周时,BIF相比德谷胰岛素的HbA1c自基线变化治疗差异为0.06%(90%CI -0.11, 0.24;P=0.56),达到非劣效。
  • BIF和德谷胰岛素治疗均使空腹血糖自基线显著降低;第26周时BIF vs 德谷胰岛素的组间差异为4.7 mg/dL(90%CI 0.1, 9.3;P=0.09)。
  • 2级低血糖发生率低且两组无显著差异(BIF 0.22事件/患者/年 vs 德谷胰岛素0.15事件/患者/年;P=0.64),无严重低血糖。
  • BIF与德谷胰岛素治疗中出现的不良事件发生情况相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Basal insulin Fc (BIF) (insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for once-weekly basal insulin administration. This phase 2 study assessed the safety and efficacy of BIF versus degludec in insulin-naive patients with type 2 diabetes (T2D) previously treated with oral antihyperglycemic medications. RESEARCH DESIGN AND METHODS: During this randomized, parallel, open-label study, 278 insulin-naive patients with T2D were randomly assigned (1:1) to receive BIF once weekly or degludec once daily over the 26-week treatment period. Both groups were titrated to fasting glucose of 80-100 mg/dL (4.4 to <5.6 mmol/L). The primary end point was HbA1c change from baseline to week 26 (noninferiority margin 0.4%). Secondary end points included fasting blood glucose (FBG), six-point glucose profiles, and rate of hypoglycemia. RESULTS: After 26 weeks of treatment, BIF demonstrated a noninferior HbA1c change from baseline versus degludec, with a treatment difference of 0.06% (90% CI -0.11, 0.24; P = 0.56). Both BIF and degludec treatment led to significant reductions in FBG from baseline. At week 26, the between-treatment difference for BIF versus degludec was 4.7 mg/dL (90% CI 0.1, 9.3; P = 0.09). The rate of level 2 hypoglycemia was low and not significantly different between treatment groups (BIF 0.22 events/patient/year, degludec 0.15 events/patient/year; P = 0.64); there was no severe hypoglycemia. The occurrence of treatment-emergent adverse events was also similar between BIF and degludec. CONCLUSIONS: Once-weekly BIF achieved excellent glycemic control similar to degludec, with no concerning hypoglycemia or other safety findings.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Bue-Valleskey JM, Kazda CM, Ma C, et al. Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial. Diabetes Care. 2023. PMID: 36944059. doi:10.2337/dc22-2396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。